Established
Supported by converging, mature evidence for the bounded statement being made.
Glycome Atlas
Loading reviewed Atlas content…
Glycome Atlas
How the Atlas is built
The Atlas separates source data, editorial explanation, and evidence assessment so readers can see what came from where—and where uncertainty remains.
Coverage
Coverage version 2026.07-launch-48 defines 48 launch topics across eight pillars. It is a curated map of high-value concepts, not a claim to contain every glycan, enzyme, method, or disease association.
Taxonomy
Each entry is explicitly typed as a molecule, protein, process, method, disease link, or concept. Pillars are navigation lenses: an entry may appear in more than one pillar, but it has one canonical URL and primary pillar.
Evidence language
Supported by converging, mature evidence for the bounded statement being made.
Supported by multiple lines of evidence, with meaningful limitations or incomplete generalizability.
Early or limited evidence that is useful for orientation but not a settled conclusion.
Credible sources disagree, results vary materially, or the direction of evidence is unresolved.
Citation count is never converted into a strength label. A grade appears only where an editor has assigned one to a bounded clinical or research relationship.
Editorial states
Registry imports
The import pipeline never crawls an entire registry. It reads only accession IDs already selected for Atlas entries, normalizes deterministic structure fields, records checksums and transformed paths, and defaults to a dry run. Imported data cannot overwrite explanatory text, clinical interpretation, citations, or editorial review fields.
What is not included
The public Atlas does not calculate a personal or universal glycan score. Any future composite index would require independent validation, calibration, uncertainty reporting, and a separate approval gate before implementation.